Q1 2022

Filed May 16, 2022 · 10-Q · 46 days after period end · 0001410578-22-001669

Q1 2022 · 10-Q

Revenue

$2.47M

no prior Q1 2021 on file

Net Income

-$174.22K

no prior Q1 2021 on file

EPS Diluted

-$0.08

no prior Q1 2021 on file

Gross Profit$1,992,829—

Operating Income

Same quarter

no prior Q1 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end

Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR